Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …

Radiation pneumonitis and subsequent radiation pulmonary fibrosis are the two main dose-
limiting factors when irradiating the thorax that can have severe implications for patients' …

Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis
using animal models, yet few of these compounds have replicated these beneficial effects in …

Cytokine storm, multiorgan failure, and particularly acute respiratory distress syndrome
(ARDS) is the leading cause of mortality and morbidity in patients with COVID-19. A …

Background Early detection and treatment for interstitial lung disease (ILD) in patients with
rheumatoid arthritis (RA) may ameliorate disease progression. The objective of this study …

Exposure to ionising radiation results in mutagenesis and cell death, and the clinical
manifestations depend on the dose and the involved body area. Reducing carcinogenesis in …

Background Pirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety
of in vitro and animal models of lung, liver and renal fibrosis. These pathologies share many …

Three recent clinical trials on the pharmacologic treatment of idiopathic pulmonary fibrosis
(IPF) mark a new chapter in the management of patients suffering from this very severe …

In this study, we evaluated the potential anti-fibrotic property of neferine, a
bisbenzylisoquinline alkaloid extracted from the seed embryo of Nelumbo mucifera Gaertn …

Cardiac fibroblasts (CFs) are the primary cell type responsible for cardiac fibrosis during
pathological myocardial remodeling. Several studies have illustrated that pirfenidone (5 …